CEPHIA holds steering committee meeting in San Francisco.
Steering committee Chair Tom Quinn is shown on the right next to CEPHIA phase II Principal Investigator Chris Pilcher.
Following is a summary from Tom Quinn.
Advisory Committee Meeting of CEPHIA.
The Second Advisory Meeting on CEPHIA was convened from Sept 30-Oct 1, 2013 for a two day meeting organized by Gary Murphy and held at the Blood Systems Research Institute in San Francisco, California. The Advisory Committee consisted of Thomas Quinn of Johns Hopkins University and NIAID, Anita Sands of WHO, David Burns of NIAID, Anatoli Kamali of IAVI, and Tim Hallett of Imperial College (by teleconference).
At the conclusion of the meeting, the Advisory Committee complimented the CEPHIA Team on their excellent progress over the past two years and the enormous amount of data that had been collected and presented to the Committee. The Committee reviewed the latest results from CEPHIA and was impressed with the quality and comprehensive nature of the work. The development of the specimen repository, assay protocols, and initial assays evaluation and performance were exemplary, and program target and timelines were being met on time. CEPHIA now has one of the best and well-characterized specimen repositories for assay evaluation for incidence estimation in nearly any population. Data were presented for the evaluation of 7 assays including LAg, BED, Bio-Rad avidity, Architect avidity, Vitros Avidity, Vitros Detuned and GEENIUS. Analysis tools and data from these evaluations were also posted on the CEPHIA website making it widely available.
The Advisory Committee made several recommendations including:
1. Rapid publications reflecting all the work undertaken by CEPHIA. This was discussed at length in terms of the number of papers, their topics, their authorship and other details.
2. Data should be made more widely available to other international bodies—UNAIDS, WHO, CDC, Companies and so forth.
3. CEPHIA should continue its current work on final evaluation of the remaining assays as described in the original proposal.
4. The aims of CEPHIA 1 should be separate from CEPHIA 2 as much as possible so that CEPHIA 1 could be completed and that the Committee would advocate to Gates Foundation that an no-cost extension be supported to complete all of the objectives of CEPHIA 1 independent of CEPHIA 2.
5. There was discussion about overall coordination of all the activities between CEPHIA, UNAIDS, WHO, CDC, NIH, manufacturers, etc and the need for a secretariat that coordinated these activities.
6. There was also discussion about co-funding future activities and the committee recommended that the leadership of CEPHIA should approach and discuss the role that OGAC can play.
7. It was agreed by the Committee that a teleconference report reflecting the above comments and review should be done with Christine Rousseau of the Gates Foundation. This call was held in late October, 2013.